Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on April 2, 2025
Tilray Shifts Cultivation of its Flagship Canadian Cannabis Brand and Strain, Good Supply Jean Guy, to Masson-Angers Facility in Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Quebec, April 02, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness industries, and a leader …
Tilray Transfère la Culture de Sa Marque et de Sa Variété Canadienne Emblématique, Good Supply Jean Guy, à son Installation de Masson-Angers au Québec
GlobeNewswire
·
April 2, 2025
MASSON-ANGERS, Québec, 02 avr. 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), un leader mondial des biens de consommation, de l’industrie du cannabis, des boissons et du bien-être, ainsi qu'un acteur clé sur le …
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
GlobeNewswire
·
April 2, 2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, …
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
GlobeNewswire
·
April 2, 2025
NEWTON, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer …
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
GlobeNewswire
·
April 2, 2025
During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC) …
Tonix Pharmaceuticals to Present at the 2025 Jones Trading Healthcare and Innovation Conference
GlobeNewswire
·
April 2, 2025
CHATHAM, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman M.D., …
Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases
GlobeNewswire
·
April 2, 2025
The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this previously undruggable target Nurix received a $15 …
Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
GlobeNewswire
·
April 2, 2025
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and …
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer
GlobeNewswire
·
April 2, 2025
Damien McDonald appointed CEO, effective as of May 12, 2025 Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in …
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
GlobeNewswire
·
April 2, 2025
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold …
Former EPA Flint Emergency Coordinator Expands Groundbreaking Drinking Water Training Program
GlobeNewswire
·
April 2, 2025
CHICAGO, April 02, 2025 (GLOBE NEWSWIRE) -- Environmental …
The Ensign Group Adds Two Operations in California
GlobeNewswire
·
April 2, 2025
SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the EnsignTM group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and …
The Ensign Group Expands in California
GlobeNewswire
·
April 2, 2025
SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and …
The Ensign Group Purchases Two Facilities in Washington
GlobeNewswire
·
April 2, 2025
SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and …
Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
GlobeNewswire
·
April 2, 2025
MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica BROOMFIELD, Colo., April 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “ …
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
GlobeNewswire
·
April 2, 2025
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
Global NK Cell Therapy Clinical Trials FDA Approval Patent Market Size Report 2025
GlobeNewswire
·
April 2, 2025
Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global Natural Killer (NK) Cell Therapy Clinical Trials, Proprietary Technologies, Collaborations and Market Opportunity Insight 2025 Report Highlights and Findings: Global …
VISTA Inhibitor Clinical Trials Market Size FDA Approval Patent Report 2025
GlobeNewswire
·
April 2, 2025
Delhi, April 02, 2025 (GLOBE NEWSWIRE) -- Global VISTA Inhibitor Clinical Trials, Drug Development Opportunities …
Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
GlobeNewswire
·
April 2, 2025
Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive care, oncology and dermato-oncology, today announced the …
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
GlobeNewswire
·
April 2, 2025
CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemia Final European Commission decision expected by June 2025; UK regulatory submission foreseen via …